SCHEMBL1154956

SCHEMBL1154956

CN1CCN(C2CC(c3nc(-c4ccc5ccc(-c6ccccc6)nc5c4)c4c(O)nccn34)C2)CC1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 19/20 0.83
CYP3A4 P08684 9/20 0.83
MAPK3 P27361 2/20 0.83
MAPK1 P28482 2/20 0.83
MAPK6 Q16659 1/20 0.83
INSR P06213 4/20 0.65
KDR P35968 2/20 0.60
RIPK2 O43353 1/20 0.60
ROCK2 O75116 1/20 0.60
LATS1 O95835 1/20 0.60
LCK P06239 1/20 0.60
LYN P07948 1/20 0.60
RET P07949 1/20 0.60
ABCB1 P08183 1/20 0.60
MET P08581 1/20 0.60
FGFR1 P11362 1/20 0.60
INSRR P14616 1/20 0.60
FECH P22830 1/20 0.60
MARK3 P27448 1/20 0.60
FLT4 P35916 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19264161 0.91 IGF1R (0.82) IGF1RCYP3A4MAPK3MAPK1MAPK6
SCHEMBL1315173 0.91 IGF1R (1.00) IGF1RCYP3A4MAPK3MAPK1MAPK6
SCHEMBL30909656 0.91 IGF1R (1.00) IGF1RCYP3A4MAPK3MAPK1MAPK6
SCHEMBL400255 0.91 IGF1R (1.00) IGF1RCYP3A4MAPK3MAPK1MAPK6
SCHEMBL10225428 0.91 IGF1R (0.82) IGF1RCYP3A4MAPK3MAPK1MAPK6
SCHEMBL1155082 0.90 IGF1R (0.83) IGF1RCYP3A4MAPK3MAPK1MAPK6
SCHEMBL10225527 0.88 IGF1R (0.94) IGF1RCYP3A4MAPK3MAPK1MAPK6
SCHEMBL401097 0.88 IGF1R (0.94) IGF1RCYP3A4MAPK3MAPK1MAPK6
SCHEMBL13842374 0.85 IGF1R (0.86) IGF1RCYP3A4MAPK3MAPK1MAPK6
SCHEMBL1154828 0.83 IGF1R (0.66) IGF1RCYP3A4MAPK3MAPK1MAPK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. 2011-02-24 US claimed
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. 2011-02-24 US disclosed
EP-2250173-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI Pharmaceuticals, Inc. (US) 2010-11-17 EP disclosed
WO-2009091939-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS OSI PHARMACEUTICALS, INC. (US) 2009-07-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046144-A1 IMIDAZOPYRAZINOL DERIVATIVES FOR THE TREATMENT OF CANCERS IGF1R, IGFBP3, INSR IGF1R 1/4885CYP3A4 265/4885MAPK3 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.